SummaryNinety-two patients with acute pelvic inflammatory disease were part of a double-blind clinical trial of the anti-inflammatory drug, oxyphenbutazone.The length of hospital stay was significantly reduced. Other parameters suggested improvement with the trial drug against a placebo. No side-effects were noted, ft is suggested that oxyphenbutazone is a valuable addition to antibiotic therapy in the treatment of acute pelvic inflammatory disease.